Yeruusaalem, 11 Oktoobar, 2026 (TPS-IL) — Madaxa Shirkadda Teva Pharmaceuticals, Richard Francis, ayaa qiyaasay in dakhliga sanadlaha ah ee daaweynta schizophrenia ee shirkadda uu gaari karo $1.5 bilyan ilaa $2 bilyan, ka dib markii Ururka Cuntada iyo Dawooyinka ee Mareykanka (FDA) uu ansixiyay daroogadeeda cusub ee WELTRUZA.
Dabada bishii lagu durayo ee maalinlaha ah, oo ku saleysan olanzapine, ayaa loogu talagalay in laga reebo baahida kiniiniyada maalinlaha ah iyo kormeerka caafimaad ee qasabka ah ka dib markii la siiyo, taasoo wax ka qabaneysa caqabadaha waaweyn ee ku saabsan u hoggaansanaanta daaweynta. Hadafka iibka wuxuu isku daraa WELTRUZA iyo daaweynta kale ee Teva ee la durayo ee daba-dheer ee schizophrenia, UZEDY, oo isticmaalda risperidone. Laba wax soo saar ayaa bartilmaameedsanaya bukaanada u gudbaya daawooyin afka laga qaato oo kala duwan waxaana la filayaa inay isku buuxiyaan halkii ay si toos ah ula tartami lahaayeen.
Teva waxay qorsheyneysaa inay bilowdo furitaanka Mareykanka toddocyada soo socda, inkastoo dakhli weyn la filayo kaliya rubucii labaad ee 2027, maadaama caymiska iyo aqbalaadda isbitaalada ay qaadato waqti.
Ansixinta ayaa horumarinaysa istaraatiijiyadda Teva ee ah in la ballaariyo daawooyinka cusub ee qiimaha sare leh.